The team is exploring whether biomarker testing could also identify patients who benefit more from immune checkpoint inhibitors after radiation.

After establishing dosing and safety in Phase I, researchers will evaluate the drug's anti-tumor activity in patients with PSMA-expressing cancers.

The firm said it is in discussions with the FDA to resubmit its biologics license application seeking approval for Ebvallo.

DCx sees potential to build multifunctional ADCs using the same technology Repare used to create its small molecule synthetic lethal therapies.

The firm is studying the combination in the first-line setting for head and neck cancer patients who had a PD-L1 combined positive score of less than 1.

The biotech has nominated MB-111, a drug it's developing as a treatment for elevated triglycerides, as its first clinical development candidate.

Researchers at AACR discussed what's next for the drug class, given the disappointing activity of tiragolumab with Tecentriq ...

A trial by MSK researchers has shown that neoadjuvant treatment with GSK's Jemperli spared 80 percent of patients with dMMR ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...